

December 11, 2023

Perseus Proteomics, Inc.

President & CEO: Takuya Yokokawa

e-mail: ir@ppmx.com

PPMX-T003 Phase I Interim Report Presented at 65th ASH Annual Meeting and Exposition

Perseus Proteomics Inc. is pleased to announce that the interim report of phase I clinical trial of PPMX-T003 among polycythemia vera ("PV") patients was presented by Prof. Tomoki Ito from Kansai Medical University and Dr. Teruhito Takakuwa from Graduate School of Medicine of Osaka Metropolitan University at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition on December 9, 2023 (PST) in San Diego Convention Center and online.

Title: Interim Phase I Safety Study of Anti-Transferrin Receptor
Antibody (PPMX-T003) in Patients with Polycythemia Vera

Abstract Number: 1825

Outline:

PPMX-T003, a human monoclonal antibody, targets TfR1 that is related to iron intake into cells. The main purpose of the phase I clinical trial is to confirm the safety and pharmacokinetics of PPMX-T003 through initial administration from 0.25 mg/kg to gradual increase up to 1.0 mg/kg in case of insufficient efficacy. The interim result showed that adverse events level was the same as the result of the trial in healthy volunteers and that all the erythrocyte parameters including hematocrit and hemoglobin pointed efficacy. Half life of PPMX-T003 was limited to only 12 hours or less even at the highest dose (0.64 mg/kg), which showed the antibodies were consumed by erythroblasts that perform significant hemoglobin synthesis in the bone marrow.

■ About Perseus Proteomics

Perseus Proteomics is a biotech venture established in February 2001, aiming to develop novel antibody therapeutic drugs mainly for cancer. PPMX-T003 is a first-in-class TfR1 blocking antibody obtained from the library rich in diversity using the ICOS screening method (patent No. JPB4870348). Currently, investigator-led phase I/II clinical trial of PPMX-T003 among aggressive NK-cell leukemia (ANKL) patients is also underway. The Company has been developing PPMX-T002, RI labelled antibody, and PPMX-T004, antibody drug conjugate (ADC), as well.

<https://www.ppmx.com/en/>

END